Posts in Knowledge Base

Nitrosamines: From Crisis Response to Business as Usual

What began as an urgent, industry-wide safety review of nitrosamine impurities has settled into a permanent feature of pharmaceutical quality management. The call-for-review deadlines have[…]

ATMPs: The Regulatory Path for Advanced Therapies

Cell and gene therapies are among the most promising — and most complex — medicines in development. Advanced therapy medicinal products follow a dedicated regulatory[…]

Serialisation and the Falsified Medicines Directive in Greece

Every prescription pack in Europe now carries a unique code and a tamper-evident seal. For companies supplying Greece, the country’s late arrival to this system[…]

How Medicines Are Priced in Greece: A Practical Guide

Pricing a medicine in Greece is not a negotiation in the usual sense — it is largely a calculation, driven by the prices of other[…]

Real-World Evidence: From Nice-to-Have to Decision-Maker

The randomised controlled trial remains the gold standard — but it no longer stands alone. Real-world evidence is increasingly shaping both regulatory approval and reimbursement[…]

The Qualified Person: The Signature That Releases a Batch

No batch of medicine reaches a patient in the EU until one named individual takes personal legal responsibility for it. Understanding the Qualified Person’s role[…]

Paediatric Investigation Plans: Planning for the Youngest Patients

For most new medicines, developing for adults is only part of the obligation. The Paediatric Investigation Plan determines what a company must do for children[…]

The Clinical Trials Regulation: Life After the Transition

Since the start of 2025, there is only one way to run a clinical trial in the EU. The Clinical Trials Regulation and its portal,[…]

The IVDR: Extended Deadlines, but No Room for Complacency

The In Vitro Diagnostic Regulation reshaped how diagnostics reach the EU market — and while transition deadlines have been extended, the conditions attached to them[…]

The Clinical Trials Regulation and CTIS: One Portal, One Assessment

The Clinical Trials Regulation (EU) No 536/2014 has reshaped how trials are authorised across Europe. Since the three-year transition period closed on 31 January 2025,[…]

1 … 3 4 5 6 7 … 9